Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Trial Parameters
Brief Summary
This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18. 2. Histologically or cytologically confirmed advanced non-small cell lung adenocarcinoma(stage IIIB\~IV). 3. Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefitinib, Erlotinib, Icotinib) or third generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib) monotherapy for the first time (patients who have been using first- or third-generation EGFR-TKIs for less than 28 days can be enrolled). 4. Patients positive for EGFR gene mutation (deletions in exon 19 and L858R in exon 21 of the EGFR gene), with disease progression after receiving chemotherapy can be enrolled. 5. Confirmed by investigators, tumor tissue can't be surgically excised. 6. No prior exposure to elemene injectable and/or oral emulsion within one month. 7. Prior exposure to other Chinese patent medicine with similar efficacy within one month. If more than one month, pati